Here, we report results from a retrospective analysis of the RANGE study using a comprehensive biomarker approach of PD-L1 status, tumor microenvironment gene expression signatures, and molecular subtyping, to identify patients who may optimally benefit from ramucirumab therapy for UC. This evidence concerns the gene CD274 and neoplasm.